Apimeds Pharmaceuticals (APUS) Q3 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on Apitox, a bee venom-based therapeutic for osteoarthritis and multiple sclerosis, with exclusive U.S. rights and ongoing FDA approval efforts.

• Completed IPO in May 2025, raising $11.9 million in net proceeds to fund operations and R&D.

• No revenue generated to date; operations funded by equity and related party debt.

Financial highlights

• Net loss of $1.78 million for Q3 2025, up from $0.33 million in Q3 2024; net loss of $4.85 million for the nine months ended September 30, 2025, up from $1.08 million year-over-year.

• Operating expenses for Q3 2025: $619,693 in R&D and $1,224,546 in G&A, both significantly higher than prior year.

• Cash balance of $6.99 million as of September 30, 2025, compared to $3,455 at December 31, 2024.

• No revenue recognized in the reporting periods.

Outlook and guidance

• Cash on hand and IPO proceeds expected to fund operations for at least 12 months from the reporting date.

• Management anticipates continued operating losses as R&D and regulatory activities progress.